JPM vs PACB Stock Comparison

JPM currently leads PACB in this stock comparison, with AIQ scores of 64 vs 48. The clearest difference is risk resilience, while PACB has the stronger momentum profile.

Market data as of Nov 18, 2026 market close· AIQ score gap 16 points
JPM
Financial Services
vs
PACB
Healthcare
JPM
JPMorgan Chase & Co.
Leads
Price
$324
Day move
-1.77%
AIQ Score
64/100
Best edge
Risk Resilience
Sector
Financial Services
PACB
Pacific Biosciences of California, Inc.
Price
$1.83
Day move
+0.55%
AIQ Score
48/100
Best edge
Momentum
Sector
Healthcare

What is the main difference between JPM and PACB?

JPM leads the current stock comparison as JPMorgan Chase & Co., with the clearest separation coming from risk resilience and the broader AIQ evidence mix.

AlgovestIQ AIQ Comparison

JPMorgan Chase & Co. vs Pacific Biosciences of California, Inc.

Data as of Nov 18, 2026· market close· Cross-sector · Financial Services vs Healthcare· Coverage 65/66 fields· High confidence
AIQ VerdictFragileAIQ Comparison Conviction 6/10

JPM leads

JPM leads by 16 AIQ points, primarily on Risk Resilience and Quality, but the lead has narrowed from 19 points over 30 sessions.

Fragile: 3 of 6 evidence groups support JPM, its lead is narrowing, and its current signal state is conflicted.

Evidence agreement: 3 of 6Comparison trend: Weakening
JPM

JPMorgan Chase & Co.

Leads
AIQ Score
64/100
AIQ Edge Score
8/10
PACB

Pacific Biosciences of California, Inc.

AIQ Score
48/100
AIQ Edge Score
4/10

The Algovestiq AIQ Score currently favors JPM over PACB, 64 versus 48 as of Nov 18, 2026. JPM's advantage is driven primarily by stronger risk resilience and quality, while PACB holds the stronger momentum profile. JPM also shows the stronger technical structure relative to its 50-day moving average. 3 of 6 covered evidence groups favor JPM today, and the comparison is rated Fragile on stability: only 3 of 6 covered evidence groups agree. JPM lead: Weakening — the AIQ differential moved from 19 to 16 points over 30 sessions.

Compare JPMorgan Chase & Co. and Pacific Biosciences of California, Inc. across the Algovestiq AIQ Score, valuation, quality, momentum, risk, technicals and analyst expectations.

Currently unavailable

Performance over time

Total return with distributions reinvested, from daily closes.

JPM
+123.4%
PACB
-91.9%

Total return comparison

Growth of $10,000, distributions reinvested

JPM $22,337 · PACB $807

Split-adjusted closes; each distribution is reinvested at the close on its ex-dividend date. Taxes and trading costs are not modeled.

Compare JPM and PACB against another ticker

Open a multi-ticker workspace without changing this focused pair page.

Basic: 2 symbols·Explorer: 3 symbols·Pro and Premium: 5 symbols·Your limit: 2

AIQ Factor Divergence

Where the two separate, on the four dimensions behind the AIQ Score. Bars read outward from a shared zero: further from the centre is a wider gap.

JPM advantage
0
PACB advantage
  • Risk Resilience87 vs 24
    JPM +63
  • Quality86 vs 32
    JPM +54
  • Momentum67 vs 84
    PACB +17
  • Value10 vs 23
    PACB +13

3 of 6 evidence groups favor JPM. JPM’s edge is concentrated in risk resilience and quality; PACB keeps a meaningful momentum edge.

What changed since the last close

Latest scored session 2026-11-18, compared against the prior scored session 2026-11-17.

JPM0 AIQ

No factor moved materially.

New signals

  • Drawdown Recovery Signal — bullish, risk_regime, long horizon (-9.0%)
  • MACD Histogram Expanding Bullish — bullish, momentum, short horizon
PACB0 AIQ

Largest factor move: Value -1, not enough on its own to move the overall score.

New signals

  • Low Volume Rally Warning — bearish, volume, short horizon (0.56x)
  • Stochastic Oversold Bounce — bullish, momentum, short horizon

JPM's lead was unchanged in the latest session.

Deeper signal detail for each name lives on its own signals page — JPM and PACB both carry a full feed there.

The central trade-off

JPM (JPMorgan Chase & Co.): the stronger current systematic profile, led by risk resilience and quality.

PACB (Pacific Biosciences of California, Inc.): the counter-case, on momentum, value, fundamentals — but at materially higher volatility, 114.1% against 27.4%.

Which one fits your objective

The same two names rank differently depending on what you are optimizing for. All six reads are shown at once — none of them is hidden behind a toggle.

Balanced

JPM

JPM on the overall AIQ Score, which weights Quality and Value most heavily.

Growth

PACB

PACB on combined revenue and EPS growth.

Value

PACB

PACB on the peer-relative Value factor, by 13 points.

Momentum

PACB

PACB on the Momentum factor, by 17 points.

Lower downside

JPM

JPM on Risk Resilience, by 63 points.

Analyst upside

JPM

JPM on implied upside to the consensus price target.

AIQ vs Wall Street

Where the systematic read and the analyst consensus line up — and where they do not.

MeasureJPMPACBNote
Implied upside to target+15.1%+5.2%JPM has more room
Target dispersion+30.3%+59.7%Lower is tighter analyst agreement
ConsensusBuyHoldContext, not a primary driver
Analysts covering268Higher coverage generally improves confidence

Analyst targets are expectations, not predictions. Dispersion matters as much as the midpoint.

AIQ Agreement Matrix

3 of 6 covered evidence groups favor JPM. A wide gap backed by one group is a weaker case than a narrow gap backed by five.

Evidence groupFavorsReading
AIQ ScoreJPM64 vs 48
FundamentalsPACBon balancerevenue growth -7.6% vs 4%; EPS growth -27.6% vs 14.3%; TTM ROE 4.1% vs 61.7%; gross margin 63.2% vs 34.5%; operating margin 28.2% vs -99.6% — PACB takes 3 of 5 decided legs, not all of them
ValuationPACBValue 10 vs 23
TechnicalsPACBPrice vs 50-day -4.8% vs -8.7%; vs 200-day 6.6% vs 22.4%
Risk ResilienceJPMRisk Resilience 87 vs 24
Analyst expectationsJPMTarget upside 15.1% vs 5.2%

✓ agrees with the overall verdict · ✕ points the other way. Groups marked “not covered” lack data on one or both of JPM and PACB and are excluded from the count.

AIQ Decision Stability

Fragile

The conclusion is sensitive to small changes. Treat the lead as provisional and watch the flip conditions below.

  • The AIQ gap is wide at 16 points. (supports the conclusion holding)
  • Only 3 of 6 covered evidence groups agree. (argues the conclusion is provisional)
  • The leader's advantage has been narrowing. (argues the conclusion is provisional)
  • The lead has been steady session to session. (supports the conclusion holding)
  • The leader is throwing conflicting signals. (argues the conclusion is provisional)

Stability combines the score gap, how broadly the evidence agrees, how steady the lead has been across daily snapshots, the current signal state on both names, and analyst dispersion on JPM.

How the comparison changed

120 daily snapshots · Jun 1 – Nov 18

JPM lead: Weakening — the AIQ differential moved from 19 to 16 points over 30 sessions.

Jun 1JPM leads above the line · PACB leads belowNov 18
Today
JPM +16
64 vs 48
7 sessions ago
JPM +16
65 vs 49
30 sessions ago
JPM +19
63 vs 44
90 sessions ago
JPM +33
63 vs 30

The lead has not changed hands in this window.

AIQ Signal Divergence

Only the signals that bear on the head-to-head. A conflicted name is carrying bullish and bearish rules at the same time — the technical evidence is not pointing one way.

JPMConflicted

6 bullish / 1 bearish / 1 neutral, conflicted

Only JPM

  • Bollinger Band Squeeze — neutral, volatility, short horizon (5.9%)
  • Drawdown Recovery Signal — bullish, risk_regime, long horizon (-9.0%)
  • MACD Histogram Expanding Bullish — bullish, momentum, short horizon
  • TRIX Bullish Signal — bullish, momentum, short horizon
  • Uptrend Structure Active — bullish, trend, long horizon
PACBConflicted

3 bullish / 3 bearish / 1 neutral, conflicted

Only PACB

  • ATR Expansion - Breakout Mode — neutral, volatility, short horizon (14.16%)
  • Beta Spike Warning — bearish, risk_regime, long horizon
  • MACD Histogram Expanding Bearish — bearish, momentum, short horizon
  • Stochastic Oversold Bounce — bullish, momentum, short horizon

Both carry 3 more signals that do not separate them: Golden Cross Active, EMA Ribbon Expansion Bullish, Low Volume Rally Warning.

JPM leads the comparison while carrying a conflicted signal state, which is one reason the stability rating is not higher.

Price vs model alignment

Whether the latest session's price move confirms what the model did over the same session, or contradicts it.

JPMNo material change

Neither the price nor the AIQ Score moved enough in the latest session to confirm or contradict the other (price -1.77%, AIQ 0 points).

PACBNo material change

Neither the price nor the AIQ Score moved enough in the latest session to confirm or contradict the other (price +0.55%, AIQ 0 points).

What would flip this result

A state, not a forecast. These are the specific, observable changes that would reverse the verdict — not a price prediction.

  1. 1PACB closes the Risk Resilience gap — currently 63 points behind, the largest single contributor to JPM's edge.
  2. 2PACB's Beta Spike Warning resolves — a bearish risk_regime rule currently active against it.
  3. 3JPM's conflicting signal state resolves bearish — it currently carries 6 bullish and 1 bearish rules at once.
  4. 4The narrowing continues — the lead has already given back 3 points over 30 sessions, and a further 16-point move would eliminate JPM's advantage entirely.

The full evidence

Every number behind the verdict. The leader is called above each group so you are not left to solve it from the table.

Fundamentals

PACB leads on balance
MetricJPMPACB
Revenue growth (YoY)-7.6%4%
EPS growth (YoY)-27.6%14.3%
Gross margin63.2%34.5%
Operating margin28.2%-99.6%
Return on equity (TTM)4.1%61.7%
Debt to equity3.32-11.49

Performance

PACB leads 4 of 6 windows
MetricJPMPACB
1 week (5 sessions)3.5%-13.1%
1 month (20 sessions)1.9%13.3%
3 months (63 sessions)-4.1%62%
6 months (126 sessions)16.2%75%
Year to date7.4%4.8%
1 year (252 sessions)8%12.6%

Technicals

PACB has the stronger structure
MetricJPMPACB
RSI (14)56.143.1
ADX (14)1827.4
Price vs 50-day-4.8%-8.7%
Price vs 200-day6.6%22.4%
Volatility (1M, annualized)27.4%114.1%

Risk

JPM is the more resilient
MetricJPMPACB
Beta0.782.1
Sharpe ratio0.440.61
Sortino ratio0.610.96
Max drawdown-15.5%-58.4%
Current drawdown-5.2%-32.4%
Annualized volatility22.7%93.5%
Value at risk (95%)-2.4%-9%

Straight answers

Each answer is regenerated from the current snapshot, not written once and left to age.

Which is better, JPM or PACB?

On the Algovestiq AIQ Score, JPM is the stronger of the two as of Nov 18, 2026, scoring 64 against PACB's 48. The edge comes from risk resilience and quality. PACB is not without a case — it holds the better momentum profile, which matters more if that is the objective you are optimizing for. This is a systematic score, not a recommendation: it ranks the two on the same evidence, it does not know your holding period or tax position.

Is JPM or PACB the better buy right now?

JPM carries the stronger systematic profile as of Nov 18, 2026, and the comparison is rated Fragile — 3 of 6 covered evidence groups agree. A Fragile rating means the conclusion is sensitive: only 3 of 6 covered evidence groups agree. Treat the lead as provisional.

Why does the AIQ Score favor JPM over PACB?

The composite weights Quality, Value, Momentum and Risk Resilience. JPM leads Risk Resilience by 63 points; JPM leads Quality by 54 points; PACB leads Momentum by 17 points. Where the two split, the factor with the larger weight carries the result.

Which has more analyst upside, JPM or PACB?

Analyst price targets imply +15.1% upside for JPM and +5.2% for PACB, so the Street currently favors JPM. The model and the Street agree here, which is a broader base of evidence than either alone. Analyst targets are expectations, not predictions, and dispersion matters as much as the midpoint.

Which is better value, JPM or PACB?

PACB is the better-valued of the two on the peer-relative Value factor. PACB on the peer-relative Value factor, by 13 points. The Value factor reads valuation relative to sector peers and to the company's own fundamental quality, so it is not the same as simply having the lower multiple.

Which has stronger growth, JPM or PACB?

PACB on combined revenue and EPS growth. Growth here is measured on reported revenue and earnings, not on forward estimates — it describes what the businesses have delivered, not what the Street expects next.

Which has stronger momentum, JPM or PACB?

PACB on the Momentum factor, by 17 points. Momentum is one of the four weighted factors in the AIQ composite. It has documented persistence over three- to twelve-month horizons, which makes it a timing input rather than a reason to hold something indefinitely.

Which is riskier, JPM or PACB?

JPM is the more resilient of the two, so the other name carries the higher downside risk. JPM on Risk Resilience, by 63 points. Risk Resilience is a weighted factor in the composite; position sizing usually responds to it more usefully than the buy/avoid decision does.

Is JPM more profitable than PACB?

The profitability evidence is mixed: gross margin 63.2% vs 34.5%; operating margin 28.2% vs -99.6%; ttm roe 4.1% vs 61.7%. JPM leads on two measures and PACB on one measure, and there is no single profitability composite that resolves the split — which of the two reads as "more profitable" depends on whether you weight pricing power or operating leverage.

Is JPM's lead over PACB getting stronger or weaker?

JPM lead: Weakening — the AIQ differential moved from 19 to 16 points over 30 sessions. This is measured from 120 daily comparison snapshots between 2026-06-01 and 2026-11-18. The lead has not changed hands in that window.

What would change the JPM vs PACB verdict?

The result is a state, not a forecast, so it changes when the underlying evidence changes. Concretely: PACB closes the Risk Resilience gap — currently 63 points behind, the largest single contributor to JPM's edge; PACB's Beta Spike Warning resolves — a bearish risk_regime rule currently active against it; JPM's conflicting signal state resolves bearish — it currently carries 6 bullish and 1 bearish rules at once; the narrowing continues — the lead has already given back 3 points over 30 sessions, and a further 16-point move would eliminate JPM's advantage entirely.

What do the current signals say about JPM and PACB?

JPM: 6 bullish / 1 bearish / 1 neutral, conflicted. PACB: 3 bullish / 3 bearish / 1 neutral, conflicted. A conflicted state means bullish and bearish rules are active on the same name at once — the technical evidence is not pointing one way, and a decision taken on it carries more timing risk. The most decision-relevant rule on JPM is Golden Cross Active (bullish, long horizon). On PACB it is Golden Cross Active (bullish, long horizon).

Compare JPM and PACB with others

Continue your research

This page answers which of the two. These answer the questions on either side of it.

How this comparison is scored

The Algovestiq AIQ Score composites four factors — Quality, Value, Momentum and Risk, each carrying a fixed weight. Sentiment is reported separately as SentimentPulse and is not folded into the composite. Scores refresh every trading day, and this page regenerates from the latest snapshot rather than being written once.

The verdict names a leader, states how broadly six independent evidence groups agree, and rates how durable that conclusion is given the score gap, its recent trajectory and the current signal state on both names.

How to use side-by-side comparison →

This comparison is informational and educational, not investment advice. AIQ scores update daily; re-check after earnings, guidance or macro data that materially changes either name’s factor profile.